Clinical Trial Update: Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

View source ↗

Summary

The trial evaluated organ-specific responses to the combination of atezolizumab and bevacizumab in advanced hepatocellular carcinoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: CHA University | Conditions: Advanced Hepatocellular Carcinoma | Status: COMPLETED | Results posted: 2025-12-12